The combination of anti-CTLA-4 and PD-L1 in the metareview was noted to have a higher incidence rate (13.6% of patients experienced any grade of colitis, and 9.4% experienced grade 3 or 4 colitis) [18]. This evidence concerns the gene CTLA4 and colitis.